Cost-effectiveness of dasatinib and nilotinib for imatinib-resistant or -intolerant chronic phase chronic myeloid leukemia

Authors: Professor Ken Stein , Hoyle M, Liu Z, Moxham T, Rogers G
Published: 13th October 2011
Theme: Complex Care
Type: Paper
DOI: 10.1016/j.jval.2011.07.006 Â Â

Reference:

Hoyle M, Rogers G, Moxham T, Liu Z, Stein K. Cost-effectiveness of dasatinib and nilotinib for imatinib-resistant or -intolerant chronic phase chronic myeloid leukemia. Value in Health 2011;14(8): 1057-1067.